Pharma Start-up APC to Create 20 Jobs in Two Years

Winner of the NovaUCD 2011 Start-Up Award, pharmaceutical research and technologies company APC plans to create 20 high-skill jobs in the next two years.

The company was co-founded earlier this year by Professor Brian Glennon and Dr. Mark Barrett as a spin-out from UCD’s School of Chemical and Bioprocess Engineering and already included many of the top 10 pharmaceutical companies in the world on its client list.

It provides pharmaceutical processing technologies and customized solutions to pharmaceutical companies that require the delivery of their medicines to the global market in a lean, reliable, and robust manner.

APC has already hired three permanent, PhD-qualified engineers and chemists.  Most of the 20 jobs to be created will be at the Ph.D. level, with individuals also having expertise in pharmaceutical technology and process development.

By integrating its advanced engineering and scientific competencies, APC enables pharmaceutical companies to deliver their medicines to market quicker, leaner, more reliable, and more cost-effective.

It does so by providing these companies with engineering and technology solutions that deliver cycle time improvements, yield and capacity increases, improved impurity reductions, better control of product characteristics, and reductions in batch rejections.

APC has expanded internationally and acquired clients in pharmaceutical manufacturing, research, and technology divisions throughout mainland Europe and the USA.

It invests in technology research and development and plans to launch additional products, services, and processing technologies in 2013.

APC Founders

Brian Glennon APC joined the UCD School of Chemical and Bioprocess Engineering in 1995. Before joining UCD, he worked as a Merck Sharp & Dohme chemical engineer. He is the leader of the UCD Pharmaceutical Process Engineering Research Group and deputy director of the Solid State Pharmaceutical Cluster, a Science Foundation Ireland-funded Strategic Research Cluster.

Dr. Mark Barrett APC joined the UCD School of Chemical and Bioprocess Engineering in 2009. Previously he worked as a process development engineer at Schering-Plough. He has led national and international industrial research activities since joining the UCD Pharmaceutical Process Engineering Research Group.

In addition to the NovaUCD 2011 Start-Up Award, APC was got a cheque for €5,000, €6,000 worth of professional services from Deloitte, €3,000 worth of legal services from Arthur Cox, €1,000 worth of business and taxation consultancy from Delaney Financial Consultancy and NewMarket Partnership and six-months free desk space at NovaUCD.

APC will also receive a year’s free subscription to AccountsIQ software, allowing SMEs to manage their accounting requirements via the Internet.

About APC

Founded: 2011
Industry: Pharmaceutical Manufacturing
Company Size: 51-200 employees
Headquarters: Dublin, Ireland

APC (Applied Processes Company) is a pioneering pharmaceutical company based in Dublin, Ireland, renowned for its commitment to revolutionizing the drug development process. Founded with a vision to expedite the delivery of life-changing medicines to patients, APC has positioned itself at the forefront of the pharmaceutical industry, continually driving scientific breakthroughs and championing innovative process development.

Primarily, APC serves as a strategic partner to biopharma companies, harnessing its unique blend of expertise in process development, organic and process chemistry, chemical and bioprocess engineering, and advanced statistical and analytical methodologies. The company operates globally, engaging with clients across multiple modalities, from synthetics to cutting-edge cell and gene therapies.

Critical to APC's success is its embrace of radical collaboration and commitment to lightning-fast development. By delivering more Chemistry, Manufacturing, and Controls (CMC) outcomes per unit of time than their peers, they've established a track record of significantly reducing drug development timelines.

At APC, the team's focus is not just on speed but also on quality. They strive to ensure right-first-time performance across the product lifecycle, eliminating rework and failures from clinical and commercial supply. As a result, their clients can maintain momentum on their journey to deliver crucial medicines to their patients.

In the ever-evolving pharmaceutical landscape, APC stands out with its client-centric approach. They believe in asking insightful questions to unlock key insights, aiming to propel medicines from molecule to market faster. This level of engagement has made them an invaluable ally to their clients, who are on a mission to save lives.

With its headquarters in Dublin, APC embodies Irish innovation, contributing significantly to the country's reputation as a hub for pharmaceutical and biotechnological advancement. As they continue to push the boundaries of science and engineering, APC remains steadfast in their mission - to help deliver life-saving medicines to patients faster than ever before.

Also see: Big Pharma Whistleblower in COVID-19 Pfizer vaccine.

About UCD Biopharmaceutical Engineering

UCD Biopharmaceutical Engineering is integral to University College Dublin (UCD), Ireland's largest and most diverse university. As a premier academic division within UCD's College of Engineering and Architecture, the Biopharmaceutical Engineering program aims to provide high-quality education and research opportunities in biopharmaceuticals.

Established with a clear vision to drive innovation and excellence in the biopharmaceutical industry, UCD Biopharmaceutical Engineering focuses on equipping students with a strong understanding of the principles and practices that underpin this highly specialized field. The program is tailored to impart essential technical skills, coupled with a deep understanding of the biopharmaceutical industry's complex regulatory and economic landscape.

In addition to delivering a comprehensive curriculum, UCD Biopharmaceutical Engineering also fosters a dynamic research environment. The program is spearheaded by a cadre of accomplished faculty members actively involved in pioneering research in various areas of biopharmaceutical engineering. Their research work and academic prowess ensure that students are kept abreast of the latest advancements and trends in the industry.

UCD Biopharmaceutical Engineering maintains strong connections with leading pharmaceutical and biotechnology companies nationally and globally. These industry linkages offer students invaluable exposure, enabling them to apply their theoretical knowledge in practical, real-world settings.

In postgraduate studies, UCD Biopharmaceutical Engineering offers an array of research-led master's and Ph.D. programs, providing students with opportunities to delve into advanced topics and conduct original research under the guidance of experienced faculty.

At UCD Biopharmaceutical Engineering, the commitment to academic excellence, groundbreaking research, and industry engagement positions its graduates as future leaders in biopharmaceutical engineering, ready to contribute to the ongoing evolution of this vital industry.